Halozyme to Report Third Quarter 2022 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its third quarter 2022 financial and operating results on November 8, 2022, after the market closes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its third quarter 2022 financial and operating results on November 8, 2022, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss these results. Interested parties can register for the call here, and a live webcast will also be available on Halozyme's investor relations site. Halozyme, known for its ENHANZE® technology, aims to enhance patient experiences through innovative biopharmaceutical solutions.
Details
News Market Reaction – HALO
The recorded move for HALO in the trading session of this news was +0.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading.
Halozyme will host a conference call on Tuesday, November 8, 2022 at 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr.
A live webcast and replay of the conference call will also be available online on the investor relations section of the Halozyme Therapeutics corporate website at www.halozyme.com.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO™ and NOCDURNA® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2022-financial-and-operating-results-301658185.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.